# Rishi Gupta

> Rishi Gupta is a Series A investor at OrbiMed backing Biotechnology and Health Care. See 12 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors)
- Total investments: 12
- Last investment: Sep 2025
- Lead investor: 42%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/rishi-gupta-371149

Rishi Gupta is a Series A investor at OrbiMed focused on Biotechnology and Health Care. Rishi Gupta, J.D., is a Private Equity Partner. Previously, he was a healthcare investment banker at Raymond James & Associates, served as Manager of Corporate Development at Veritas Medicine, and was a summer associate at Wachtell, Lipton, Rosen & Katz. Mr. Gupta has published scientific articles on the mechanisms of HIV entry intohost cells and legal articles on intellectual property laws in the developing world. He received his A.B. degree magna cum laude in Biochemical Sciences from Harvard College and holds a J.D. from the Yale Law School.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 7 | 58% |
| Health Care | 4 | 33% |
| Therapeutics | 4 | 33% |
| Medical | 2 | 17% |
| Retail | 1 | 8% |

15 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 7 | 58% |
| Series B | 3 | 25% |
| Seed | 1 | 8% |
| Angel | 1 | 8% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 7 | 58% |
| India | 1 | 8% |
| United Kingdom | 1 | 8% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| CHARM Therapeutics | CHARM Therapeutics uses deep learning on 3D molecular configurations to develop molecule therapeutics to target pathogenic proteins. | $80M | Series B | Sep 02, 2025 |  |
| Helicore Biopharma | Helicore Biopharma is at the forefront of developing cutting-edge treatments for obesity and related disorders. | $65M | Series A | Jan 28, 2025 |  |
| Aer Therapeutics | Aer Therapeutics is a clinical-stage biopharmaceutical company that develops an approach to treat lung disease with excess mucus and mucus plugs. The company focuses on treating respiratory diseases with significant unmet needs, such as COPD, cystic fibrosis, and asthma. | $36M | Series A | Apr 13, 2023 |  |
| Delfi Diagnostics | Delfi Diagnostics detect cancer early, when it is most curable, using high precision non-invasive blood tests. It uses artificial intelligence and genome sequencing to detect unique patterns of DNA fragmentation in the blood of patients. | $225M | Series B | Jul 18, 2022 |  |
| CHARM Therapeutics | CHARM Therapeutics uses deep learning on 3D molecular configurations to develop molecule therapeutics to target pathogenic proteins. | $50M | Series A | Jun 09, 2022 |  |
| Delfi Diagnostics | Delfi Diagnostics detect cancer early, when it is most curable, using high precision non-invasive blood tests. It uses artificial intelligence and genome sequencing to detect unique patterns of DNA fragmentation in the blood of patients. | $101.1M | Series A | Jan 12, 2021 |  |
| Enliven Therapeutics | Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.The company's discovery process combines clinically validated biological targets and industry-leading chemistry to address the limitations of existing therapies. This approach allows us to efficiently and effectivelydevelop precision oncology therapeutics that enhance overall patient well-being.Founded in July 2019 by Sam Kintz, MBA, Joe Lyssikatos, PhD, and Anish Patel, PharmD, Enliven Therapeutics is based in Boulder, Colorado. | $55M | Series A | Dec 07, 2020 |  |
| Modis Therapeutics | Modis Therapeutics is bringing disease-modifying therapies to patients with rare genetic diseases. | $30M | Series A | Oct 01, 2018 |  |
| Turnstone Biologics | Turnstone Biologics is a privately-held clinical-stage biotech company. Turnstone Biologics’ mission is to deliver breakthrough cancer immunotherapies by advancing two leading and complementary platforms targeting tumor immunity, to improve survival for people with cancer. | $41.4M | Series B | Nov 02, 2016 |  |
| Attenua | Attenua, Inc. is a virtual biotech company formed to develop therapies for debilitating conditions neglected by Big Pharma's shift to specialty Pharma and biologics. They believe small molecule Blockbuster drugs that would benefit millions are still to be discovered.They have assembled a team of leading scientists and ex-Big Pharma advisorswith many years of drug development expertise. Their team has previous work experience at Merck, GSK, AstraZeneca, and Genentech. | $35M | Series A |  |  |

10 of 12 investments shown.

## Co-investors
- [F-Prime](https://shizune.co/investors/profile/f-prime-capital-partners) — VC Fund, 7 deals together
- [Khosla Ventures](https://shizune.co/investors/profile/khosla-ventures) — VC Fund, 4 deals together
- [OUP (Osage University Partners)](https://shizune.co/investors/profile/osage-university-partners) — VC Fund, 3 deals together
- [5AM Ventures](https://shizune.co/investors/profile/5am-ventures) — VC Fund, 2 deals together
- [AV8 Ventures](https://shizune.co/investors/profile/av8-ventures) — VC Fund, 2 deals together
- [Cowen Healthcare Investments](https://shizune.co/investors/profile/cowen-healthcare-investments) — VC Fund, 2 deals together

## About OrbiMed

VC Fund · New York, United States

OrbiMed is a healthcare-dedicated investment firm, with approximately $5 billion in assets under management. OrbiMed's investment advisory business was founded in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies. OrbiMed manages the Caduceus Private Investmentsseries of venture capital funds and a family of public equity investment funds.

5 contacts available at OrbiMed.

| Name | Title | Profile |
| --- | --- | --- |
| Dina Chaya | Partner | https://shizune.co/investors/profile/dina-chaya |
| Kevin Koch | Venture Partner | https://shizune.co/investors/profile/kevin-koch |
| Rishi Gupta | Private Equity Partner | https://shizune.co/investors/profile/rishi-gupta |
| Sunny Sharma | Senior Managing Director | https://shizune.co/investors/profile/sunny-sharma |
| Tadd S. Wessel | Managing Director | https://shizune.co/investors/profile/tadd-s-wessel |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Rishi Gupta invest in?

Rishi Gupta invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Rishi Gupta last invest?

The most recent investment recorded for Rishi Gupta closed in Sep 2025. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co